SCHEMBL1495765

SCHEMBL1495765

Cc1ccc(-c2cc(C(=O)O)cc(C(=O)N3CCC(O)C3)c2)cc1

nearest known ligand 0.46

Predicted protein targets (top 18)

geneUniProtsupporting neighboursconfidence
DHODH Q02127 1/20 0.46
LOXL2 Q9Y4K0 2/20 0.45
MEN1 O00255 2/20 0.43
KMT2A Q03164 2/20 0.43
CYP46A1 Q9Y6A2 1/20 0.43
HDAC4 P56524 1/20 0.42
KDM1A O60341 2/20 0.42
HRH3 Q9Y5N1 1/20 0.42
PROKR1 Q8TCW9 1/20 0.41
HSP90AA1 P07900 1/20 0.41
HSP90AB1 P08238 1/20 0.41
CCNC P24863 2/20 0.41
CDK8 P49336 2/20 0.41
ATM Q13315 1/20 0.41
RAB9A P51151 1/20 0.41
ACACB O00763 1/20 0.41
ACACA Q13085 1/20 0.41
CDK19 Q9BWU1 1/20 0.41

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL1495764 1.00 DHODH (0.46) DHODHLOXL2MEN1KMT2ACYP46A1
SCHEMBL1495725 0.90 DHODH (0.50) DHODHPROKR1
SCHEMBL8008656 0.85 TDP1 (0.48) LOXL2KMT2AHRH3CCNCCDK8
SCHEMBL2760898 0.84 PARP1 (0.46) DHODHMEN1KMT2AKDM1APROKR1
SCHEMBL2761212 0.81 DHODH (0.52) DHODHKMT2AKDM1ARAB9A
SCHEMBL1495462 0.81 HPGD (0.55) DHODHMEN1KMT2AKDM1ARAB9A
SCHEMBL13486885 0.81 KMT2A (0.62) MEN1KMT2AHDAC4
SCHEMBL10195732 0.81 KMT2A (0.62) MEN1KMT2AHDAC4
SCHEMBL12121182 0.81 KMT2A (0.62) MEN1KMT2AHDAC4
SCHEMBL2760988 0.80 HPGD (0.58) DHODHMEN1KMT2AKDM1ARAB9A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20150266822-A1 Amide Compounds, Compositions And Uses Thereof RENOVIS, INC. 2015-09-24 US claimed
EP-2262766-A2 AMIDE COMPOUNDS, COMPOSITIONS AND USES THEREOF Renovis, Inc. (US) 2010-12-22 EP claimed
WO-2009110985-A2 AMIDE COMPOUNDS, COMPOSITIONS AND USES THEREOF RENOVIS, INC. (US) 2009-09-11 WO claimed
EP-2262766-B1 AMIDE COMPOUNDS, COMPOSITIONS AND USES THEREOF EVOTEC AG (DE) 2015-11-11 EP disclosed
US-20150266822-A1 Amide Compounds, Compositions And Uses Thereof RENOVIS, INC. 2015-09-24 US disclosed
US-8946439-B2 Amide compounds, compositions and uses thereof EVOTEC AG (DE) 2015-02-03 US disclosed
US-20110065681-A1 AMIDE COMPOUNDS, COMPOSITIONS AND USES THEREOF EVOTEC AG (DE) 2011-03-17 US disclosed
EP-2262766-A2 AMIDE COMPOUNDS, COMPOSITIONS AND USES THEREOF Renovis, Inc. (US) 2010-12-22 EP disclosed
WO-2009110985-A2 AMIDE COMPOUNDS, COMPOSITIONS AND USES THEREOF RENOVIS, INC. (US) 2009-09-11 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20110065681-A1 AMIDE COMPOUNDS, COMPOSITIONS AND USES THEREOF IL1B, ADORA2B, AVPR1B DHODH 3626/4885LOXL2 2529/4885MEN1 2911/4885
US-20150266822-A1 Amide Compounds, Compositions And Uses Thereof IL1B, ADORA2B, AVPR1B DHODH 3626/4885LOXL2 2529/4885MEN1 2911/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.